ArticleRenal failure2025
Smurf2 knockdown attenuates the progression of diabetic nephropathy by inhibiting mesangial cell proliferation and fibrosis through suppressing EYA2 ubiquitination.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is a serious microvascular complication of diabetes and the main cause of end-stage renal disease. Smurf2 is a member of ubiquitin ligases. In this study, we aimed to investigate the mechanism by which Smurf2 mediated the development of DN. C57BL/6 mice were intraperitoneally injected into streptozotocin to construct a DN mouse model, and mouse mesangial cells (MCs) were treated with high glucose (HG) to establish a cell model. A cell counting kit 8, EDU staining and Western blot assay were performed to assess cell proliferation and fibrosis. The interaction between Smurf2 and EYA2 was identified by immunoprecipitation, and the ubiquitination of EYA2 was detected by Western blot. In addition, the kidney injury of DN mice was evaluated by hematoxylin-eosin and Masson staining and the detection of biochemical parameters. Results suggested that Smurf2 expression was increased in DN mouse model and HG-treated MCs; Smurf2 knockdown inhibited cell proliferation and fibrosis in HG-treated MCs. Mechanically, Smurf2 knockdown inhibited the ubiquitination on EYA2, leading to the suppression of EYA2 degradation and an upregulation in EYA2 protein levels. Moreover, EYA2 knockdown restored cell proliferation and fibrosis in HG-treated MCs inhibited by Smurf2 knockdown. Additionally, Smurf2 knockdown inhibited kidney injury and fibrosis in DN mouse model. In conclusion, we demonstrated that Smurf2 knockdown attenuated the progression of DN by inhibiting MCs proliferation and fibrosis through suppressing EYA2 ubiquitination, which may provide a novel insight into the pathogenesis of DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.